Angiotensin-converting enzyme inhibitors: synthesis and biological

Scott D. Larsen, Mark A. Connell, Michele M. Cudahy, Bruce R. Evans, Paul D. May, Martin D. Meglasson, Theresa J. O'Sullivan, Heinrich J. Schostarez, ...
0 downloads 0 Views 1MB Size
Download PDF
434

J . Med. Chem. 1985,28,434-442

Angiotensin-Converting Enzyme Inhibitors: Synthesis and Biological Activity of Acyl Tripeptide Analogues of Enalapril William J. Greenlee,*+Patricia L. Allibone,? Debra S. Perlow,? Arthur A. Patchett,? Edgar H. Ulm,' and Theodore C. Vassil' Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065, and Merck Institute for Therapeutic Research, West Point, Pennsylvania 19486. Received April 9, 1984

The synthesis and biological activity of a series of inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) are described. Incorporation of the substituted N-carboxymethyl dipeptide design of enalapril (MK-421) into acyl tripeptides and larger peptides yielded potent inhibitors of the enzyme. These can be viewed as substrate analogues in which the carbonyl of the scissile peptide bond is replaced by a CHCOzH group. Several of the analogues described possess inhibitory potency equal to that of enalaprilat (MK-422), but none achieves an increase in potency which would demonstrate additional binding interactions contributed by the extended peptide chain. Application of the design described may be useful for inhibition of other metallopeptidases.

Previous reports from these laboratories have described the design and development of potent inhibitors of angiotensin-converting enzyme. Among these are enalapril (MK-421) and its parent diacid enalaprilat (MK-422)' as well as lactam inhibitom2 These substituted N carboxymethyl dipeptide inhibitors are tripeptide analogues in which the carbonyl of the scissile 40-NH- bond is replaced by a CH-COZH gr0up.l In this view a hypoPhCH2CH2CH-NH-CH-CC-N C02R I

C.H3

? C02H

Enalapril R

=

(MK-421)

Et (maleate s a l t )

Enalaprilat

(MK - 4 2 2 )

Ph I Ph CO-NH-CH CH-NH-CH I

C.H2C02H

- C-

C.H3

fl

N

? C02H

1 -

followed is illustrated for compound 1 (Scheme I). As many of the compounds of interest possess one chiral center more than does enalapril, use of optically active aldehydes as starting materials was desirable. These were available in N-protected form by using published procedures. Aldehydes 8, 13, and 14 were prepared by reduction of the Boc-protected esters with diisobutylaluminum hydride.s The ester precursor of aldehydes 14 and 15 was obtained by standard Arndt-Eistert homologation of Nt-B~c-phenylalanine.~ Aldehyde 16 was prepared by hydrolysis of the acetal.

R =H

thetical picture of the binding of enalaprilat to angiotensin-converting enzyme encompasses interactions with the Si,Si, and S1subsites of the active site3 (Figure 1). The importance of the interaction of the CHCOzHgroup of the N-carboxymethyl dipeptides with the active site zinc atom of angiotensin-converting enzyme is indicated by the marked increase in inhibitor potency for enalaprilat relative to that for the inhibitory peptides N-benzoyl-PheAla-Pro (Table I) and t e p r ~ t i d e . Thus ~ far, no examples of tetrapeptides or larger inhibitors have been reported in the N-carboxymethyldipeptide series! V inhibitors of this type can be designed to interact with the Sz and S3subsites, binding tighter than that observed for enalaprilat may result. That interactions with the Sz and S3 subsites of the active site of angiotensin-converting enzyme can contribute to binding is indicated by the marked increase in inhibitor potency resulting from the addition of acylamino substituents to dipeptide analogues 2 (compounds 3-5, Table I). A similar effect of an acylamino group was reported for ketone tripeptide analogues 6 and 7.6,6 In order to explore the possibility of a similar result for the N carboxymethyl dipeptides, compound 1 and several other tripeptide analogues were studied. The synthesis and biological activities of these compounds are reported below. Synthesis The acyl tripeptide analogues were prepared by using a Strecker condensation as the key step.' The route 'Rahway, NJ. West Point, PA. 0022-2623/S5/1828-0434$01.50/0

(1) Patchett, A. A.; Harris, E.; Tristram, E. W.; Wyvratt, M. J.;

Wu, M. T.; Taub, D.; Peterson, E. R.; Ikeler, T. J.; ten Broeke, J.; Payne, L. G.; Ondeyka, D. L.; Thorsett, E. D.; Greenlee, W. J.; Lohr, N. S.; Hoffsommer, R. D.; Joshua, H.; Ruyle, W. V.; Rothrock, J. W.; Aster, S. D.; Maycock, A. L.; Robinson, F. M.; Hirschmann, R.; Sweet, C. S.; Ulm. E. H.; Gross, D. M.; Vassil, T. C.; Stone, D. A. Nature (London) 1980,288, 280. (2) Thorsett, E. D.; Harris, E. E.; Aster, S.; Peterson, E. R.; Taub, D.; Patchett, A. A.; Ulm, E. H.; Vassil, T. C. Biochem. Biophys. Res. Commun. 1983, I l l , 166. Thorsett, E. D.; Harris, E. E.; Aster, S.; Peterson, E. R.; Patchett, A. A. In "Peptides: Structure and Function", Proceedings of the 8th American Peptide Syniposium, Hruby, V. J., Rich, D. H., Eds.; Pierce Chemical Co., Rockford, IL, 1983; pp 555-559. Wyvratt, M. J.; Tischler, M.; Ikeler, T.; Springer, J. P.; Tristram, E. W.; Patchett, A. A. Ibid. pp 551-554. Parsons, W. H.; Davidson, J. L.; Taub, D.; Aster, S. D.; Thorsett, E. D.; Patchett, A. A.; Ulm, E. H.; Lamont, B. I. Biochem. Biophys. Res. Commun. 1983,117, 108. (3) The notation of Schechter and Berger is used: Schechter, I.; Berger, A., Biochem. Biophys. Res. Commun. 1967, 27, 157. (4) Petrillo, E. W.; Ondetti, M. A. Med. Res. Rev. 1982, 2, 141. (5) Natarajan, S.; Condon, M. E.; Nakane, M.; Reid, J.; Gordon, E. M.; Cushman, D. W.; Ondetti, M. A. in "Peptides: Synthesis-Structure-Function", Proceedings of the 7th American Peptide Symposium, Rich, D. H., Gross, E., Eds.; Pierce Chemical Co., Rockford, IL, 1981; pp 429-433. (6) Meyer, R. F. Nicolaides, E. D.; Tinney, F. J.; Lunney, E. A.; Holmer, A.; Hoefle, M. L.; Smight, R. D.; Essenberg, A. S.; Kaplan, H. R.; Almquist, R. G. J . Med. Chem. 1981,24, 964. (7) Greenlee, W. J. Tetrahedron Lett. 1982, 23, 3995. (8) Rich, D. H.; Sun, E. T.; Boparai, A. S. J. Org. Chem. 1978,43, 3624. Ito, A.; Takahashi, R.; Baba, Y. Chem. Pharm. Bull. Jpn. 1975,23, 3081. (9) Chaturvedi, N. C.; Park, W. K.; Smeby, R. R.; Bumpus, F. M. J. Med. Chem. 1970,13,177. Ondetti, M. A.; Engel, S. L. Ibid. 1976, 18, 761. Stachowiak, K.; Khosla, M. C.; Puclinska, K.; Khairallah, P. A.; Bumpus, F. M. Ibid. 1979, 22, 1128. 0 1985 American Chemical Society

Angiotensin-Converting Enzyme Inhibitors

Journal of Medicinal Chemistry, 1985, Vol. 28, No. 4 435

Ph CO-NH-CH2CHO I

16 -

BOC 13 CH2 Ph

R-NH-~H-CH~CHO

. 14-

R

= -6CC

15

R

=

-COPh

As illustrated in Scheme I, treatment of amino nitrile 9 with HC1-saturated methanol, followed by reblocking

with di-tert-butyl dicarbonate, yielded a diastereomeric mixture of amido esters lOR, 105. Treatment of the amido esters with Amberlyst 15 acidic resin in methanoPo provided diesters 11R, 115. After acylation with benzoyl chloride, the resulting diastereomeric diesters 12R, 125 were separated by chromatography on silica gel. Saponification of these afforded diacids 1R and 15, which were isolated after ion-exchange chromatography. The absolute configuration at the newly formed chiral center in 1R and 15 was assigned by comparison of their in vitro activities (Table IV) and was based on the fact that enalaprilat, with the S configuration at this center, is 200-fold more active than the corresponding R diastereomer? This relationship holds for other N-carboxymethyl dipeptide& and for lactam inhibitors.12 A similar sequence, starting with aldehyde 13, was used to prepare amido esters 17R, 175 (see Experimental Section). As this structure was chosen for analogue studies, it was deemed important to establish with certainty the absolute configuration at the newly formed chiral center. This was accomplished by conversion of 17R and 175 to the cyclic ureas 18R and 185. For the ureas, coupling constants in the ‘HNMR spectra allowed configurational assignment.13 Standard acylation and peptide coupling procedures were used to prepare the acylated analogues listed in Table IV. Ester 44 (Table 111)was prepared from the corresponding diester by selective acidic hydrolysis of the proline ester. A synthetic sequence beginning with aldehyde 14 was troublesome due to the tendency for five-membered ring lactams to form when the primary amino group was unacylated (see Experimental Section). As a result, only one diastereomeric diacid (258)was obtained (Table 11). A modified synthesis starting with benzamido aldehyde 15 afforded a mixture (2:l 255:25R) of diastereomers, although in low overall yield. A similar route with benzamido aldehyde 16 as starting material provided diacids 20 and 205 in good yield. The absolute configuration of diacids 205 and 255 was assigned (as above) on the basis of their in vitro activities relative to that observed for the (10) Greenlee, W. J.; Thorsett, E. D. J. Org. Chem. 1981,46,5351. (11) Wu, M.T.;Douglas, A. W.; Ondeyka, D. L.; Payne, L. G.; Ikeler, T. 3.; Joshua, H.; Patchett, A. A., submitted for publication (J. Pharm. Sci.). Vincent, M.; Remond, G.; Portevin, B.; Serkiz, B.; Laubie, M. Tetrahedron Lett. 1982,23,1677. (12) Wyvratt, M. J.; Tischler, M.; Ikeler, T. J.; Springer, J. P.; Tristram, E. W.; Patchett, A. A. In “Peptides: Structure and Function”, Proceedings of the 8th American Peptide Symposium; Hruby, V. J., Rich, D. H., Eds.; Pierce Chemical Co., Rockford, IL, 1983;pp 551-554. Attwood, M. R.; Francis, R. J.; Hassall, C. H.; Krohn, A.; Lawton, G.;Natoff, I. L.; NixQn, J. S.; Redshaw, S.; Thomas, W. A. FEBS Lett. 1984,165,201. (13) Jackman, L. M.;Sternhell, s. “Applications of NMR Spec-

troscopy in Organic Chemistry”; Pergamon Press: New York, 1969;pp 278-281.

185 -

Jab

-

10 Hz

18R -

Jab

=,

2 HZ

(S, S, 5 , S) I S , R , S, SI

diastereomeric mixtures (20 and 25). Results and Discussion The angiotensin-convertingenzyme inhibitory activities for the acyl tripeptide analogues are shown in Table IV. In analogue 205 the benzamidomethyl side chain was hoped to be directed into and make binding interactions in the Sz substite of the enzyme. The moderate activity for this analogue demonstrated that binding contributed by the benzamidomethyl group does not compensate for the absence of the phenethyl side chain present in enalaprilat. Moreover, acyl tripeptide analogue 15,for which binding in both S1 and S2subsites was expected, proved sixfold less active against angiotensin-converting enzyme than enalaprilat. An understanding of the origin of the reduced activity of 15 is necessary in order to design more potent inhibitors with an acyl tripeptide-like structure. One possible explanation for the reduced activity of 15 was suggested by a strong intramolecular hydrogen-bonded amide NH observed in the IR spectrum of diester 125 (3325 cm-’ in CDC13). If a similar hydrogen bond were to exist in analogue 1 s (Figure 2), energy would be required during binding in order to break this bond and permit interactions of the carboxyl and acylamino functions with the enzyme. In addition, it was felt that replacement of a peptide carbonyl of the inhibitory peptides in Table I by the CHC02H moiety of the substituted N-carboxymethyl dipeptides might result in a regional displacement of the side chain interacting with the SI subsite from its position for the bound peptide inhibitors 3-5 (or bound substrates). While flexibility in the phenethyl side chain of enalaprilat might compensate for this alteration, in the case of 15, a misorientation of the acylamino side chain may be unavoidable. Two approaches to more potent inhibitors were investigated. In acyl tripeptide analogue 32 (Table IV), intramolecular hydrogen bonding to the carboxyl is precluded. Proline is known to be accepted into the SI subsite of angiotensin-converting enzyme in substrates.14 In acyl tripeptide homologue 255 (Table IV) a longer and more flexible backbone is introduced, which we hoped would permit binding interactions with both S1 and Sz subsites. The phenylpropyl homologue of enalaprilat (1:l mixture of diastereomers) is a potent inhibitor (I5o = 8.3 nM),16 demonstrating the accommodation of the lengthened side chain in the S1 subsite of the enzyme. Moreover, an intramolecular hydrogen bond (seven-membered) seemed unlikely for 25. (14) For example, bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-PheAx). (15) Compound prepared by T. Ikeler and tested as a mixture (RS,S,S) of diastereomers.

436 Journal of Medicinal Chemistry, 1985, Vol. 28, No. 4

Greenlee et al. OR

I

I

I

/,o -c, Ph'OC

NH-CH-C-N C02R

CH2Ph

Enalaprilat (MK-422) I I

I I

S1

I

-.1s

R

=

-H

12s

R

=

-CH3

Figure 2. Intramolecular hydrogen bonding of inhibitor 1s and analogue 125.

II

Scheme I

I

>-1) H C l , CH30H

-1

I

CH30H

CONH2 COP3

Figure 1. Binding of inhibitors to the hypothetical active site of angiotensin-converting enzyme. Table I. In Vitro Angiotensin-Converting Enzyme Inhibitory Activities eh

?

CH2 R-CH-C-NH-CH-

tH3C-9 g ,

A m k r l y s t 15

BOC NH-CH-CH-NH-CH-C-N

2 ) BOCzO, E t 3 N

10R. 2 s CHZPh

-L H -cI H-N H-c H- c - N

1) ( P h C 0 ) Z O E b N , CH2ClZ

C02CH3

C OzC H3

IlR, E S

'

2 ) NaOH, Hz0-THF

I

C02H

2-5

CH2 P h PhCO-NH-CH-CH-NH-CH-C-N? I FH3 I C02R

12s R-CH-C-CH~CHZ-C-

Yz

"3

12R -

1s 1R -

,

C02H

6,7

no. 2 3

R

config 8,s

150,M

ref 3.3 X 10""' 37% 16 H SS,S 1.4 X 10" 17 NH2 s,ss 2.7 X 10" 18 4 PhCONH 17 5 P-Glu-LyS-NH S,S,S,S,S 5 X SS 2.6 x 10-3 5 6 H 8,s 1.2 x 10" 5 7 PhCONH "The figure in parentheses refers to percent inhibition at the concentration listed.

Both acyl tripeptide analogues 32 and 2 5 s proved to be more potent inhibitors than 1s but are still less active than enalaprilat. The strikingly low activity of the unacylated analogue 28 may reflect a lack of tolerance for a protonated amine, which might disrupt the interaction between the CHC02Hmoiety of 28 and the active-site zinc atom. The protonated amine groups of 34 and 36 may be sufficiently removed for this not to occur'. While the high activity of analogue 32, which lacks the aromatic side chain of enalaprilat, is interesting, it appears that here, as in lS,the acylamino side chain does not occupy a position optimal for interactions in the S2 subsite. Further support for this belief is provided by the extended tetra- and pentapeptide

P

Y C02R

R= R=

-CH3 -CH3

( S , S, S , S ) ( 5 ,R, S , S )

R-

-H -H

( S , S , S , 5) ( S , R, S , S )

R=

analogues 34, 36, 38, and 41, which exhibited inhibitor potency no greater than that of benzamido analogue 32. Conclusions It is clear from the results presented that the acyl tripeptide analogues described possess geometry which does not permit contributions to binding from both a side chain directed to the SIsubsite of angiotensin-convertingenzyme and an acylamino substituent intended to participate in multiple interactions with the enzyme. It is hoped that other modifications of the substituted N-carboxymethyl dipeptide design will establish its usefulness in an internal position of a peptide with retention of binding interactions remote from the scissile bond. This possibility is currently under study. Experimental Section All optically active amino acids used were of the L configuration. Standard abbreviations were used for the peptide derivatives, i.e., Cbz = benzyloxycarbonyl, Boc = tert-butoxycarbonyl, Phe = phenylalanine, p-Glu = pyroglutamic acid, Ala = alanine, Pro = proline, Lys = lysine, and for the following: TFA = CF3C02H, DPPA = diphenylphosphoryl azide. N-Hydroxysuccinimide esters of protected amino acids were purchased from Sigma Chemical

Journal of Medicinal Chemistry, 1985, Vol. 28, No.4 437

Angiotensin-Converting Enzyme Inhibitors

Table 11. Physical Properties of N-[Carboxy(benzamidophenylalkyl)methyl]-~-alanyl-~-prolines and Analogues F;'2 y 3 R 1- N H - C H- ( C H 2 ) n - C H - N H - C H-t! -N I COR3

p

?

COR4

no. 19 19s 20 20s lOR, 10s 21s 12s 12R

R1

R2

n

R3

PhCO PhCO PhCO PhCO Boc Boc PhCO

H H H H CH2Ph CHzPh CHzPh

0

OCH, OCH, OH OH NH2 OCH, OCH,

0

0 0 0 0 0

R4 OCH, OCH, OH OH OCH, OCH, OCH3

config RS,S,S

mp, "C oil

S,S,S,

104-105

RS,S,S

glass glass

S,RS,S,S

177-183 75-76 120-122 168-170 214-2 16e

s,s,s

S,S,S,S S,S,S,S

S,R,S,S

yield, 70 45 45 86 78 44 37 55

formula" CzoH27N306"/2HzOb C20H27N306f/2H20 C18H23N306 C18H23N306d c24H36N406 C26H37N307

C27H33N306 C27H33N306

96 s,s,s s CHzPh 0 PhCO OH OH C25H29N306 1R S,R,S,S glass 90 C25H29N306 24 Boc CHzPh 1 NH2 OCH, S,S,S,S oil 18 C2SH39N307 OH OH S,RS,S,S CHzPh 1 25 PhCO glass 59 C26H31N306*~/2Hz0 "Unless otherwise indicated, all compounds gave satisfactory ( i 0 . 4 % )combustion analyses (C, H, N). bCalcd: C, 57.96. Found: C, 58.53. 'Calcd: C, 57.28. Found C, 59.57. dCalcd C, 57.28. Found: C, 58.59. eDecomposes.

1s

9

Table 111. Physical Properties of N-[Carboxy(N-alkanoyl-2-pyrrolidinyl)methyl]-~-alanyl-~-prolines

3

&H-NH-CH-c-N

R I1

COR2

yH3

no. R1 R2 R3 config 175 Boc 2" OCH, S,S,S,S 17R Boc 2" OCH, S,R,S,S 27 Boc OCH, OCH3 S,S,S,S 28 H OH OH s,s,s,s CH&O OCH, OCH, S,S,S,S 29 CHaCO OH OH s,s,s,s 30 31 PhCO OCH, OCH, S,S,S,S 32 PhCO OH OH s,s,s,s OCH, OCH, S,S,S,S 33 Boc-GlyCO 34 GlyCO OH OH s,s,s,s 35 Boc-PheCO OCH, OCH, S,S,S,S,S 36 PheCO OH ~S,S,S,S OH 37 PhCO-PheCO OCH, S,S,S,S,S OCH3 38 PhCO-PheCO OH s,s,s,s,s OH 41 P-Glu-LysCO OH S,S,S,S,S,S OH 44 PhCO OEt s,s,s,s OH "All compounds gave satisfactory (f0.4%) combustion analyses (C, H, N). Co. and used as is. Melting points were recorded on a Bausch and Lomb hot-stage apparatus and are uncorrected. lH NMR spectra were taken on a Varian XL-200 FT spectrometer. Chemical shifts are reported in ppm (6) downfield from Me$i as internal standard. In many cases, alanylproline cis-trans isomers were identified in the NMR spectra by a pair of alanyl methyl doublets. In these cases, both doublets are liste4 the minor doublet (5-40% of the total) is upfield. IR spectra were taken on a Perkin-Elmer Model 297 spectrometer. The FT-IR spectrum of compound 125 was recorded on a Nicolet 7000 spectrometer. Optical rotations were measured with a Perkin-Elmer 141 automatic polarimeter and were run in CH30H. Mass spectra (MS) were taken on a Varian 731 spectromater at 70 eV. Those marked FAB were taken by using the fast atom bombardment method. Elemental analyses were performed by J. Gilbert and his associates, Merck Sharp and Dohme Research Laboratories. The existence of solvents of crystallization was confirmed by 'H NMR whenever possible. Thin-layer chromatography was performed on uniplates from Analtech coated with 250 pM of silica gel GF. Preparative-layer chromatography was carried out with 1.5- or 2-mm silica gel GF plates from Analtech. MPLC was performed with E. Merck Lobar columns or columns packed with E. Merck silica gel 60 (cat. no. 9385). The following abbreviations were used for chromatography solvents: CMWA = CHC18-CH30H-H20HOAC,EBAW = EtOAc-BuOH-HOA*H20, EPAW = EtOAcPyr:HOAcHzO. Ion-exchange chromatography was carried out on DOWEX 50W-X4 resin prewashed with HzO. Unless otherwise

C02R3 mp, "C oil oil 68-70 216-220 118-119

glass glass glass

122-124

glass oil 165-168 68-70 146-148

glass glass

yield 29 64 71 78 64 95 76 90 64 91 89 66 53 94

formula" C20H34N406 C20H34N406 C21H36N307'1/2H20 C14H23N305 C18H2BN306 C~&xiNaOa C23H31N306'1/4H20 C21H27N306'1/4NH3 C23H38N408 C16H26N408"/ C30H44N408 C23H32N406 C32H40N407 C30H36N407'1/2H20

C25H40N608'5/2H20 C23H31N306*HCl*H20

indicated, elutions were performed with H20-Pyr (25:l) and products were isolated after freeze-drying. A description of our enzyme assay has been pub1ished.l (N-Benzoy1amino)acetaldehydeDiethyl Acetal. A mixture of aminoacetaldehyde diethyl acetal (6.66g, 0.050 mmol), benzoyl chloride (7.03 g, 0.050 mmol), Et3N (5.05 g, 0.050 mmol), and CHzClz (100 mL)was stirred at 0 OC for 15 min and then at room temperature for 2 h. The mixture was filtered and evaporated. An EtOAc solution of the residue was washed with aqueous HC1 (0.5 N), H20, saturated NaHCO,, HzO, and brine and dried (MgSO,). Evaporation afforded the product (10.0 g), which was recrystallized from hexanes-EtOAc: mp 35-36 "C (lit.I9 mp 38 "C); TLC (EtOAc) R, 0.70; NMR (CDC13) 6 1.37 (6 H, t, J = 7 Hz), 3.2-4.0 (4 H, m), 3.75 (2 H, d, J = 6 Hz), 4.75 (1H, t, J = 6 Hz), 7.2-7.8 (5 H, m), 6.5 (1 H, br).

N-(2-Benzamido-1-carbomethoxyethy1)-Ala-Pro-OCH3 (19R, 19s). A mixture of the above-described acetal (2.0 g), aqueous HCl (2.0 N, 10 mL), and THF (10 mL) was stirred vigorously for 2.5 h. The mixture was then extracted several times (16) Compound prepared by Dr. E. Harris. (17) Cushman, D. W.; Pluscec, J.; Williams, N. J.; Weaver, E. R.; Sabo, E. F.; Kocy, 0.;Cheung, H. S.; Ondetti, M. A. Experimentia 1973,29, 1032. (18) Compound prepared by R. D. Hoffsommer. (19) Fisher, E. Chem. Ber. 1893,26, 464.

438 Journal of Medicinal Chemistry, 1985, Vol. 28, No. 4 Table IV. In Vitro Angiotensin-Converting Enzyme Inhibitory Activities

R I

P h C 0-N H - C H - ( C H 2 1 n - C H - N H-C H-C I C02H

-N C09H

no. 20 205 1s 1R 25 255

R

0

H

0 0 0

CHzPh CHzPh CHzPh CHzPh

config (RS.S.S) (S,S,S)

n

H

150,nM 40 17

(S,S,S,S)

7.7

(S,R,S,S) (S,RS,S,S)

1 1

(S,S,S,S)

K

1400 4.8 3.0

CO?H ~~

no. 28 30 32

34 36 38 41 enalaprilat (MK-422) captopril

R

H CHSCO PhCO NHZCHzCO NHz-Phe-CO PhCONH-Phe-CO p-Glu-Lys-CO

config

s.s.s.s

150,nM 700

with ether, and the combined organic portions were washed with HzO and brine and dried MgSO,). Evaporation gave (Nbenzoy1amino)acetaldehyde (16)as a colorless oil (1.5 g).20TLC (EtOAc) Rf 0.50; NMR (CDCl,) 6 4.25 (2 H, d, J 5 Hz), 7.4-8.0 (5 H, m), 9.80 (1 H, s). A mixture of the crude aldehyde (0.697 g, 4.27 mmol), AlaPro.l/zHzO (0.865 g, 3.89 mmol), KCN (0.277 g, 4.27 mmol), and CH3OH (7.5 mL) was stirred for 3 days. The mixture was then cooled (ice bath) as anhydrous HC1 was passed in until saturation. The mixture was tightly capped and stirred overnight at room temperature. After evaporation, the residue was taken up in CH2C1z (25 mL) and the mixture saturated with anhydrous NH,. The mixture was immediately evaporated and the residue slurried in EtOAc and filtered. The residue after evaporation was combined with Amberlyst 15resinlo (20 g) and CH,OH (50 mL). The mixture was warmed at 60 OC for 3 days. The product was eluted with CH,OH-Et,N (2:l) and purified on silica gel (EtOAc-EtOH, 20:1), giving a mixture (1:l)of diastereomers. These were separated by MPLC; more-mobile diastereomer (195):NMR (CDCI,) 6 1.30, 1.37 (3 H, 2 d, J = 7), 1.9-2.4 (4 H, m), 3.3-3.4 (1H, m), 3.5-3.8 (5 H, m), 3.80 (6 H, s), 4.5-4.6,4.6-4.7 (1 H, 2 m), 7.4-7.5 (3 H, m), 7.7-7.8 (1 H, br), 7.9-8.0 (2 H, m); IR (CHCl,) 3330, 1740, 1650, 1530, 1435 cm-l; MS (FAB), m/e 406 (M+ 1); less-mobile diastereomer (19R):NMR (CDCIJ 6 1.23,1.32 (3 H, 2 d, J = 7 Hz), 1.9-2.4 (4 H, m), 3.4-3.8 (6 H, m), 3.73, 3.75, 3.76, 3.77 (6 H, 4 s), 4.3-4.4, 4.5-4.6 (1H, 2 m), 7.10 (1H, br), 7.4-7.5 (3 H,m), 7.7-7.8 (2 H, m); IR (CHCI,) 34~3300,1730,1640,1435 cm-'; MS (FAB), m/e 406 (M+ + 1). N-(2-Benzamido-l-carboxyethyl)-Ala-Pro (20).A mixture of diesters 19R,195 (1:lratio; 68 mg, 0.17 mmol) and a 0.25 N NaOH solution (2.0 mL, 0.50 mmol) was stirred for 3 h. The mixture was neutralized by addition o 0.50 N HCl (1.0 mL) and placed onto Dowex 50W-X4 (3 9). The product was isolated as a white foam: TLC (3:l:l:l EBAW) Rf 0.25,0.30; NMR (CD,OD) 6 1.53 (minor), 1.55, 1.59 (3 H, 3 d, J = 7 Hz), 1.9-2.4 (4 H, m), 4.3-4.9 (3 H, m), 4.4-4.6 (3 H, m), 7.2-7.4 (3 H,m), 7.8-7.9 (2 H, m); MS (FAB);m/e 406 (M+ 1). Diacid 205. Diester 195 (25 mg,0.062 mmol) was treated as above, giving 205 as a white foam: TLC Rf 0.030; NMR (CD,OD) 6 1.53 (minor), 1.59 (3 H, 2 d, J = 7 Hz), 1.9-2.3 (4 H, m), 3.2-3.8 (3H, m), 4.0-4.6 (3 H, m), 7.4-7.6

+

+

(20) Bendall, M. R.;Ckwright, I. L.; Chark, P. I.; Lowe, G.; Burse,

D. Eur. J. Biochem. 1977,79,201.

Greenlee et al. (3 H, m), 7.8-7.9 (2 H, m); MS (FAB), mle 406 (M+ + 1). N - [1-Carboxamido-2-[ (tert-butoxycarbonyl)amino]-3~henylpropyl]-Ala-Pro-OCH~(105, 10R). L-N-t-Bocphenylalaninal(8) was prepared by the procedure of Rich et al.? with the exception that 2-propanol was used to quench the reaction mixture and the silica gel chromatography was omitted. The NMR spectrum of the crude aldehyde matched that reported except that traces of toluene and 2-propanol were present. The crude aldehyde was a sticky solid and was used immediately without purification. A mixture of aldehyde (5g, 20 mmol), KCN (1.3 g, 20 mmol), Ala-Pro.'/ZHzO (3.7 g, 19 mmol), and HOAc (1.2 mL, 20 mmol) in CH30H (35 mL) was stirred for 3 days. The mixture was saturated with anhydrous HCl at 0 "C and then tightly capped and allowed to stir for 24 h at room temperature. After evaporation to dryness, the residue was combined with di-tert-butyl dicarbonate (4.35 mL, 19 mmol), EbN (6.6 mL, 47.5 mmol), and CH30H (50 mL). The mixture was stirred for 3 h and then filtered and evaporated to a light-yellow oil. An EtOAc solution of the crude product was extracted with HzO, dried (MgS04),and evaporated. The product was purified on silica gel (EtOAc-EtOH, 201) and recrystallized (EtOAc-CH,OH): TLC Rf0.45,0.50; NMR (CDCI3) 6 1.10,1.17 (3 H, 2 d, J = 7 Hz), 1.25 (9 H, s), 1.8-2.0 (4 H, m), 2.6-3.1 (3 H, m), 3.30-3.5 (3 H, m), 3.83 (3 H, s), 4.0-4.1 (1H, br), 4.40 (1 H, m), 5.01 (1 H, br d, J = 8 Hz), 5.6-5.7 (1H, br), 7.1-7.3 (5 H, m); IR (CHCl,) 3500-3300, 2980, 1740, 1690, 1650 cm-l; MS, mle 476 (M+). N-[ I-Carbomethoxy-2-[ (tert -butoxycarbonyl)amino]-3phenylpropyl]-Ala-Pro-OCH3(215,21R). A mixture of amido esters 105,10R (0.800 g, 1.68 mmol), Amberlyst 15 resinlo (12 g), and CH3OH (40 mL) was warmed at 60 "C for 10 days. The residue (0.574 g) remaining after rinsing of the resin with CH30H-EbN (2:l) and evaporation was treated in CHzClz(5 mL) with di-tert-butyl dicarbonate (0.35 mL, 1.5 mmol). The product was purified on silica gel (EtOAc), giving the more-mobile (0.125 g) and less-mobile (0.304 g) diastereomers. The more-mobile diester (21R),Rf 0.40, was accompanied by impurities and was not characterized. The less-mobile diester (215), R, 0.35, showed the following properties: NMR (CDCl,) 6 1-10,1.17 (3 €I, 2 d, J=7Hz),1.25(9H,s),1.8-2.0(4H,m),2.6-3.1(3H,m),3.3-3.5 (3 H, m), 3.83 (3 H, s), 4.0-4.1 (1 H, br), 4.40 (1 H, m), 5.01 (1 H, br d, J = 8 Hz), 5.6-5.7 (1H, br), 7.1-7.3 (5 H, m); MS, m/e 491 (M+). Diester 215,when treated first with TFA and then with benzoyl chloride and triethylamine in CH2Cl2,afforded a diester identical in all respects with 125. N-(2-Benzamido-l-carbomethoxy-3-phenylpropyl)-AlaPro-OCH,(125,12R). Amido esters 105,lOR (0.944 g, 1.98 mmol) were combined with Amberlyst 15 resinlo (15 g) and CHBOH(25 mL) and the mixture warmed (60 "C) for 10 days. The residue remaining after elution of the product with CH,OH-Et,N (21)and evaporation (0.663 g) was divided and one portion (0.455 g) was combined with benzoic anhydride (0.262 g, 1.16 mmol), EbN (0.16mL, 1.2 mmol), and CHZC1, (4 mL). The mixture was stirred for 3 h and then diluted with EtOAc. The solution was extracted with aqueous NaHC08, HzO, and brine and dried (MgSO,). Chromatography on silica gel afforded the product (0.378 g, 39%) as a mixture (6:l) of diastereomers. Separation of these by MPLC (EtOAc) gave the following. More-mobile diastereomer 125: TLC R, 0.45; NMR (CDCl,) 6 1.30, 1.38 (3 H, 2 d, J = 7 Hz), 1.8-2.2 (4 H, m), 2.94 (2 H, ABX, JAB = 10,6~, = 52, Jm = 5, J B =~6), 3.26,3.36, 3.61,3.74 (6 H, 4 s), 3.28 (1 H, d, J = 3 Hz); 3.4-3.6 (3 H, m), 4.3-4.4 (1 H, m), 4.8-4.9 (1 H, m), 7.1-7.8 (11H, m); IR (CHCI,) 3350, 1730,1635, 1430 cm-'; MS, m/e 495 (M+). Less-mobile diastereomer 12R: TLC R f 0.40; NMR (CDCl,) 6 1.15, 1.23 (3 H, 2 d, J = 7 Hz), 1.8-2.2 (4 H, m), 2.94 (2 H, ABX, JAB = 14, AB = 32, JAX = 6, JBX = 8),3.4-3.6 (4 H, m), 3.70 (3 H, s), 3.74 (3 H, s), 4.4-4.5 (1 H, m), 4.6-4.8 (1H, m), 7.1-7.8 (10H, m); IR (CHC13) 3425, 1730, 1640, 1430 cm-l; MS, m/e 495 (M'). N-(2-Benzamido-l-carboxy-3-phenylpro~~l)-Ala-Pro (1% 1R). Diester 125 (77.1 mg, 0.156 mmol) was combined with aqueous NaOH (0.25 N, 1.9 mL) and the mixture was stirred for 24 h. Addition of aqueous HC1 (0.50 N, 0.90 mL) and CHBOH (1mL) gave a clear solution which was placed onto Dowex 50. Elution of the product with HzO-CH30H(51)and then HzO-Pyr (25:l) gave 15,which was recrystallized from EtOAc-CH30H: TLC (EBAW; 3:l:l:l) Rf 0.50; NMR (CD,OD) 6 1.55 (3 H, br d,

Angiotensin-Converting Enzyme Inhibitors

Journal of Medicinal Chemistry, 1985, Vol. 28, No. 4 439

101)Rf 0.10;NMR (CDC13) 6 1.35(3H, d, J = 7 Hz), 1.9-2.2(7 J = 7 Hz), 1.9-2.4(4H, m), 3.16 (2H, J = 8 Hz), 3.3-3.8(2H, H, m), 2.6-2.9(3H, m), 3.5-3.7(3H, m), 3.73(3H, 81, 5.7(2H, m), 4.3-4.5(2H, m), 4.7-4.9(1 H, m), 7.2-7.8(10H, m); MS, m/e br s), 6.6-6.8(1 H, m), 7.2(5 H, 8 ) ; MS (FAB); mle 374 (M+ + 468 (M+). Diacid 1R Diester 12R (22.4mg) was treated as for 12S, giviqg the corresponding diacid as a white foam: TLC 1). N-(3-Benzamido-l-carboxy-4-phenylbutyl)-Ala-Pro (255). (EBAW, 3:l:l:l)R, 0.50; NMR (CD30D) 6 1.50,1.59 (3 H, 2 d, A solution of amido ester 24 (117mg, 0.239mmol) in TFA (2mL) J = 7 Hz), 1.8-2.4(4H, m), 2.8-3.8(4H, m), 4.2-4.9(3H, m), was allowed to stand for 18 h and then evaporated to dryness. 7.2-7.8(10H, m); MS, m/e 468 (M'). 34(tert -Butoxycarbonyl)amino]-l-diazo-4-phenyl-2-b~-To the residue were added Et3N (0.13mL, 0.96mmol), benzoyl chloride (0.29mL, 0.25 mmol), and CH2ClZ(1 mL), and the tanone (22). To a cooled (-15 'C) mixture of N-t-Boc-phenylmixture was stirred for 18 h. A slurry of the mixture in EtOAc alanine (24g, 0.091mol), Et3N (12.7mL, 0.091mol), and ether was filtered and then washed with HzO, NaHC03 solution, and (200mL) was added ClC02Et (8.7mL, 0,091mol) with vigorous brine and dried (MgS04).Purification on silica gel (EtOAc-EtOH, stirring, After 30 min at -15 'C, excess ethereal diazomethane 3:l) gave N-(3-benzamido-l-carboxamido-4-phenylbutyl)-Alawas added over 30 min. Stirring was continued for 2 h and then Pro-OCH3(36mg, 0.072mmol, 30%): TLC Rf 0.5; NMR (CDC13) the mixture was concentrated first with a stream of nitrogen and 6 1.29(3 H, d, J = 8Hz), 1.8-2.3(5 H, m), 2.8-3.2(5 H, m), 3.3-3.6 then on the rotary evaporator. The residue was slurried in EtOAc (5 H, m), 3.73 (3 H, s), 4.3-4.7(3 H, m), 5.6-5.7(2H, m), 6.72 and filtered. The filtrate was washed with saturated NaHC03 (1H, d, J = 8 Hz), 7.1-7.2(1H, m), 7.2-7.9(10H, m); MS (FAB), and Hzband then dried (MgSO,) and concentrated. The residue mle 495 (M+ + 1). The amido ester was combined with Amberlyst was recrystallized from hexanes-EtOAc (15.4g, 59%); mp 91-93 15 resin (0.27g) and CH30H (1 mL) and the mixture warmed 'C; TLC (CH,C&-CH30H, 101)R, 0.50;NMR (CDC13) 6 1.44(9 at 60 'C for 6 days. Elution of the product from the resin H, a), 2.9-3.1 (2H, d of d, J = 7,9 Hz), 4.2-4.6(1 H, d o f t , J (CH30H-Pyr, 2:l)and purification on silica gel (EtOAc-EtOH, = 9,7 Hz), 5.2-5.5(1 H, br d, J = 8 Hz), 5.3 (1H, s), 7.2(5 H, 101) gave N-(3-benzamido-l-carbomethoxy-4-phenylbutyl)-Alae); IR (CHC13)3440,3000,2125,1705,1636,1490,1375,1165 cm-'; Pro-OCH3(18mg, 0.035mmol, 48%); TLC Rf 0.5; NMR (CDC13) -32.5' (CHSOH). Anal. (c14MS, m/e 220 (M' - 69);D"].[ 6 1.23(3H, d, J = 7 I&), 1.6-2.4(6H, m), 2.81 (2H, ABX, J A ~ HisNz03) C, H, N. = 14,6m = 34,J u = 8,JBx = 6),3.03 (1 H,q, J = 7 Hz); 3.4-3.6 Methyl 3-[( t e r t -Butoxycarbonyl)amino]-4-phenyl(2H, m), 3.62(3H, s), 3.70(3H, s), 4.2-4.3(1 H, m), 4.4-4.6(2 butanoate (23). To a solution of diazo ketone 22 (15.4g, 0.053 H, m), 7.2-7.9(10H, m). mol) in CH30H (180mL) was added a solution of silver benzoate A solution of the diester in aqueous NaOH (0.25N, 0.56mL) (0.25g) in E t N (5 mL) and the mixture was stirred until nitrogen was stirred for 4 h and then diluted with aqueous HCl (0.50 N, evolution ceased. Activated charcoal (1 g) was added and the 0.28mL). The product was purified on Dowex 50 (1 g), giving mixture filtered and evaporated. An EtOAc solution of the crude 25s (10mg, 0.021mmol) as a white foam: TLC (3:l:l:lEBAW) product was extracted with HzO and brine, then dried (MgS04), R,O.5; NMR (CD30D)6 1.2-1.8(5 H, m), 2.0-2.5(5 H, m), 3.0-3.2 and evaporated to a yellow oil. Recrystallization from hexane (2H, m), 3.6-3.9 (3 H, m), 4.4-4.7(2H, m), 7.2-7.9(10 H, m); gave a white solid (11.9g, 76%): mp 54-56 "C; TLC (CHzCl2MS (FAB), m/e 482 (M+ + 1). CHSOH, 101)Rf 0.70;NMR (CDCl3) 6 1.45 (9 H, s), 2.51(2H, d, J = 6 Hz); 2.90(2H, d of d, J = 6,8Hz), 3.72(3H, s), 3.9-4.0 3-Benzamido-4-phenylbutanal(l5).To an ice-cold solution (1H, m), 5.06(1 H, br d, J = 8Hz), 7.23(5H, s);IR (CHC133440, of ester 23 (1.33g, 4.5mmol) in toluene (20 mL) was added a 2975,1710,1495,1370,1165 cm-'; MS, m/e 220 (M+- 73); [.ImD solution (1 M) of Dibal-H in hexane (18.5mL). The mixture was stirred 1h and then treated as described for aldehyde 14,affording -20.0' (CH30H). Anal. (C16H19N04) C, H, N. 3-[(tert-Butoxycarbonyl)amino]-4-phenylbutanaldehyde after chromatography on silica gel 34(tert-butoxycarbony1)amino]-4-phenyl-l-butanol(O.425 g, 1.60mmol, 36%) as a white (14). A cooled (-78"C) suspension of ester 23 (1.04g, 3.54mmol) in ether (10mL) was stirred vigorously as diisobutylaluminum solid mp 57-59 'C; NMR (CDCl,) 6 1.40(9H, s), 1.6-1.9(2H, hydride (1 M in hexane, 8.8mL) was added over 30 min. After m), 2.83 (2H, d, J = 7 Hz), 3.5-3.9(3 H, m), 5.23 (1 H, d, J = an additional hour at -78 "C, CH30H (1mL) and then a saturated 7 Hz), 7.2(6 H, s). Anal. (Cl5Hz3NO3)C, H, N. A solution of the alcohol (0.181g, 0.683mmol) in TFA (5 mL) was allowed to solution of Rochelle salt (1mL) were added. The mixture was allowed to warm to room temperature and then diluted with ether stand for 2 h. The residue after evaporation was combined with (50 mL) and Rochelle salt solution (20mL). After extraction of benzoic anhydride (0.170g, 0.751mmol) and Et3N (0.29mL, 2.1 the aqueous layer with ether, the combined organic portions were mmol) in CHZClz(5mL) and the mixture was stirred for 2 h. The washed with H20 and brine and dried (MgS04). Evaporation gave mixture was diluted with EtOAc (25mL) and extracted with dilute the crude product which was purified on silica gel (hexane-EtOAc; NaHC03 (3 X 5 mL). Chromatography on silica gel (401 51)and then recrystallized (hexane-EtOAc), giving a white solid CHZClz-CH3OH) provided 3-benzamid0-4-phenyl-l-butanol(97.1 (0.69g, 75%): mp 88-89 'C; TLC R, 0.40;NMR (CDC13)6 1.43 mg, 0.361mmol, 53%) as a colorless oil: NMR (CDC13)6 1.3-2.0 (9H, s), 2.49 (1H, d, J = 6 Hz), 2.52(1H, d, J = 6 Hz), 2.81 (1 (2H, m), 3.03(2H, d, J = 7 Hz), 3.6-3.9(2H, m), 4.3-4.9 (1H, H, d, J = 7 Hz), 2.85 (1 H, d, J = 7 Hz), 4.0-4.3(1 H, m), 4.98 m), 5.1 (1 H, br s), 6.7-7.0(1 H, m), 7.2-7.8(5 H, m); MS, m/e (1 H, br d, J = 8 Hz), 7.2 (5 H, s), 9.60 (1 H, t, J = 2 Hz); IR 269 (M"). A solution of this alcohol (97.1mg, 0.361 mmol) in (CHC13)3400,2950,1700,1470,1370,1260,1160,1040 cm-'; MS, CHzCl2 (1mL) was added to a slurry of pyridiniutn chlorochromate m/e 263 (M'); [aIz0~ -14.8' (CH30H). Anal. (Cl4HZ1NO3)C, H, (0.12g, 0.54mmol) in CHzClz(5 mL). The mixture was stirred N. for 18 h, then diluted into EtOAc (50 mL), and filtered through N - [3 4(tert -Butoxycarbonyl)amino]-l-carboxamido-4Florisil. Silica gel chromatography(2:lhexane-EtOAc) afforded phenylbutyll-Ala-Pro-OCH3 (24). A mixture of aldehyde 14 pure aldehyde (37.5mg, 0.140mmol, 39%): mp 107-108 O C ; NMR (0.347g, 1.32mmol), Ala-Pr0.'/~H~0(0.259g, 1.32mmol), KCN (CDC13)6 2.76 (2 H, d, J = 6 Hz), 2.9-3.2(2H, m), 3.6-3.8(1 H, (0.086g, 1.32mmol), HOAc (0.076mL, 1.32mmol), and CH30H m), 4.5-4.9(1 H, m), 6.72(1H, d, J = 6 Hz), 7.2-7.8(10H, m), (3mL) was stirred for 48 h and then cooled (ice bath) and sat9.80 (1 H, s); MS, m/e 267 (M+). urated with anhydrous HCl. The flask was tightly capped and N-(3-Benzamido-l-carboxy-4-phenylbutyl)-Ala-Pro (25). the mixture was allowed to stir at room temperature for 72h. The A mixture of aldehyde 15 (35mg, 0.13mmol), Ala-Pro.l/zHzO residue after evaporation was combined with di-tert-butyl di(24.2mg, 0.13mmol), KCN (8.5mg, 0.13mmol), HOAc (7.4pL, carbonate (0.30mL, 1.32mmol), Et3N (0.70mL, 5.28mmol), and 0.13mmol), and CH30H (0.5mL) was stirred for 3 days, then CHzCl2 (3mL). The mixture was stirred (3h), then diluted with cooled (ice bath), and saturated with anhydrous HCl. The flask EtOAc (25mL), extracted with HzOand brine, and dried (MgSOJ. was tightly capped and the mixture stirred for 18 h at room

The residue after evaporation was purified on silica gel (EtOAc-EtOH, 20:1),giving the product as a single diastereomer (0.117g, 18%): TLC (EtOAc-EtOH, 101) Rf 0.50; NMR (CDCl3) 6 1.30(3H, d, J = 7 Hz), 1.40 (9H, s), 1.7-2.3 (7H, m), 2.7-3.2 (3 H, m), 3.3-3.6(2H, m), 3.73(3H, s), 4.5-4.6(3 H, m), 7.2(5 H, 8 ) ; IR (CHC13) 3400,2960,1640,1430 cm-'; MS (FAB), m/e 491 (M+ + 1). Also isolated was a single diastereomeric lactam (135mg, 21%) with the following properties: TLC (EtOAc-EtOH,

temperature. The residue after evaporation was taken up in CHZCl2and treated with anhydrous NH3. An EtOAc slurry of the product was filtered to remove NH4Cl and then silica gel chromatography (40:l CH2C12-CH30H) provided N-(3-benzamido-l-carboxamidc-4-phenylbutyl)-Ala-P~c-OCH3 (33mg, 0.067 mmol, 51%): TLC Rf 0.40;MS, m/e 494 (M+). The amido ester (30mg, 0.061 mmol) was combined with Amberlyst 15 resin (0.45 g) and CH3OH (1mL) and the mixture was stirred for 8 days at

440 Journal of Medicinal Chemistry, 1985, Vol. 28, No. 4 60 "C. Elution of the product with EbN and purification on silica gel (101 EtOAc-EtOH) gave N-(3-benzamido-l-carbomethoxy4-phenylbutyl)-Ala-Pro-OCH3(16.4 mg, 0.032 mmol, 53%) as a mixture (23) of diastereomers: TLC Rf0.50 (major), 0.55; NMR (CDC13) 6 1.23 (major), 1.28 (3 H, 2 d, J = 7 Hz), 3.64 (major), 3.72 (major),3.60,3.70 (6 H, 4 s); remainder as for 255;MS, m/e 509 (M'). A solution of the diester (14 mg,0.028 mmol) in aqueous NaOH (0.25 N, 0.45 mL) was stirred for 2 h and then diluted with aqueous HCl (0.50 N, 0.22 mL). The product was purified on Dowex 50 (1.5 g), providing 25 (12 mg, 0.025 mmol) as a white foam: TLC (3:l:l:l EBAW) Rf 0.50 (major),0.55; MS (FAB), m/e 482 (M+ + 1). N - [Carboxami do [ N - ( tert -butoxy carbon y 1 ) -2~yrrolidinyl]methyl]-Ala-Pro-OCH~ (17S,17R). A solution of N-t.Boc-Pro-OCH3 (9.0 g, 41.4 mmol) in toluene (150 mL) was cooled (dry-ice bath) as a solution (1 M in hexane) of diisobutylaluminum hydride (62.1 mL) was added over 30 min. After an additional 30 min, CH30H (3 mL) was added slowly. Then Rochelle salt (25 g) was added with vigorous stirring. The resulting thick gel was vacuum fiitered and rinsed with EtOAc. The filtrate was washed with saturated Rochelle salt solption, H20,and brine and dried (MgS04). The residue after evaporation (7.8 g) was dissolved in CH30H (60 mL), and Ala-Pro.l/zHzO (5.6 g, 28.7 mmol), KCN (2.0 g, 30 mmol), and HOAc (1.8 g, 30 mmol) were added. The resulting solution was allowed to stir for 4 days and then cooled (ice bath) and saturated with anhydrous HCl. The flask was tightly stoppered and the mixture allowed to stir for 4 days at room temperature. After evaporation and reconcentration from CH30H,the residue was taken up in CH30H (150 ml) and treated with Et3N (10 mL) and di-tert:butyl dicarbonate (6.6 mL) for 24 h. After evaporation to dryness, the residue was slurried in EtOAc and filtered. The filtrate was washed with HzO and brine and dried (MgSO4). Evaporation provided the product as an oil. Silica gel chromatography gave pure material (3.5 g, 8.2 mmol, 29%) as a mixture of diastereomers (2:l). Separation of diastereomerswas carried out by MPLC (EtOAc-EtOH, 101). yore-mobile isomer (175): TLC (EtOAc-EtOH, 101) R, 0.30; NMR (CDC13) 6 1.26 (3 H, d, J = 7 Hz), 1.44 (9 H, s), 1.8-2.4 (8 H, m), 3.2-3.4 (2 H, m), 3.5-3.7 (2 H, m); 3.71 (3 H, s); 4.1-4.2 (2 H, m); 4.5-4.6 (1H, m), 5.7 (1H, br), 7.2 (1H, br); IR (CHC13) 3500,2950,1730,1680,1620cm-I; MS, m/e 426 (M+). Less-mobile isomer (17R): TLC Rf 0.25; NMR (CDC13) 6 1.26 (3 H, d, J = 8 Hz), 1.44 (9 H, s), 1.8-2.4 (8 H, m), 3.2-3.4 (2 H, m), 3.5-3.7 (2 H, m), 3.71 (3 H, s), 4.2-4.4 (2 H, m), 4.5-4.6 (1H, m), 5.5 (1 H, br), 6.1 (1 H, br); IR (CHC13)3500,2950, 1735, 1680, 1620 cm-l; MS, m/e (M+). N-[Carbomethoxy(2-pyrrolidiny1)methyll-Ala-Pro-OCH3 (26). A mixture of amido ester 17s (0.75 g, 1.76 mmol), Amberlyst 15 acidic resin (10 g), and CH30H (20 mL) was stirred gently and warmed at 60 OC for 7 days. The product wa8 eluted from the resin with CH30H-EbN (2:l) and purified on silica gel (CMWA, 100:20:3:0,5), giving the product as the acetate salt. A CH2Clz solution of this was saturated with anhydrous NH3 and then immediately evaporated to dryness. The residue was taken up in EtOAc and filtered. Evaporation then provided the product as a thick oil (0.35 g, 1.0 mmol): TLC (CMWA,853051) Rf 0.50; NMR (CDC13)6 1.34 (3 H, d, J = 8 Hz), 1.5-2.3 (8 H, m), 3.0-3.2 (2 H, m),3.5-3.7 (2 H, m), 3.73 (3 H, s), 3.76 (3 H,s), 4.5-4.6 (1 H, m), 5.8 (2 H, br); MS (FAB), m/e 432 (M' + 1); IR (CHClJ 3350, 2960, 1730, 1630 cm-l. N -[Carbomethoxy[N-(tert -butoxycarbonyl)-2pyrrolidinyl]methyl]-Ala-Pro-OCH3 (27). Amido ester 175 (0.75 g) was treated as described above with Amberlyst 15 resin. A mixture of the crude product, di-tert-butyl dicarbonate (0.38 g, 1.8 mmol) and CHZCl2(5 mL) was allowed to stir for 2 h. The product was purified on silica gel: TLC (EtOAc) Rf 0.35; NMR (CDC13) 6 1.20, 1.26 (3 H, 2 d, J = 7 Hz), 1.46 (9 H, s), 1.8-2.3 (8 H, m), 3.3-3.7 (5 H, m), 3.71 (3 H, s), 3.72 (3 H, s), 3.7-3.9 (1 H, m), 4.2-4.3 (1H, m), 4.5-4.6 (1H, m); MS, m/e 441 (M'); IR (CHC13)2975, 2900, 1740,1680, 1650, 1410 cm-l. N-[Carboxy(2-pyrrolidinyl)methyl]-Ala-Pro (28). A solution of diester 27 (55 mg, 0.125 mmol) in aqueous NaOH (2 mL, 0.25 N)was stirred vigorously for 4 h. Aqueous HCl (1mL, 0.50 N) was added and the mixture was evaporated to dryness. The residue was then treated with TFA (4 mL) for 4 h. The product after evaporation was purified on Dowex 50 (3 9); TLC (EPAW,

Greenlee et al. 5:5:1:3) Rf 0.30; NMR (D2O) 6 1.28, 1.36 (3 H, 2 d, J = 7 Hz), 1.6-2.2 (8 H, m), 3.1-3.3 (2 H, m), 3.3-3.5 (3 H, m), 3.7-3.9 (1H, m), 4.0-4.2 (2 H, m); MS, m/e 314 (M+ + 1). N-[Carbomethoxy(N-acetyl-2-pyrrolidinyl)methyl]-AlaPro-OCH3(29). A mixture of diester 26 (0.19 g, 0.56 mmol), AczO (0.085 g, 0.83 mmol), Et3N (0.084 g, 0.83 mmol), and CHzClz(2 mL) was stirred for 4 h and then evaporated to dryness. The residue was taken up in EtOAc and filtered. The product was purified on silica gel (EtOAc-EtOH, 101) and recrystallized (hexanes-EtOAc): TLC (EtOAc-EtOH, 51) Rr 0.2; NMR (CDC13) 6 1.25 (3 H,d, J = 7 Hz), 1.8-2.3 (8 H, m), 2.1 (3 H, s), 2.4-2.6 (4H,m),3.71(3H,s),3.73(3H,s),3.83(1H,d,J=6Hz),4.3-4.4 (1H, m), 4.5-4.6 (1H, m), 4.9 (1H, br); MS, m/e 383 (M'); IR (CHCl3) 2960,2890,1740, 1430 cm-'. N-[Carboxy(N-acetyl-2-pyrrolidinyl)methyl]-Ala-Pro (30). A solution of diester 29 (50 mg, 0.13 mmol) in aqueous NaOH (0.25 N, 2.1 mL) was stirred overnight. The solution was neutralized by addition of aqueous HCl (0.50 N, 1 mL) and then placed directly onto Dowex 50 (2.5 g): TLC (EBAW, 3:l:l:l) Rf 0.15; NMR (DzO) 6,1.48, 1.56 (3 H, 2 d, J = 7 Hz), 1.7-2.3 (8H, m), 2.06 (3 H, s), 3.4-3.7 (4 H, m), 3.8-4.0 (1 H, m), 4.3-4.5 (2 H, m); MS (FAB), m/e 356 (M+ + 1). N-[Carbomet hoxy(N-benzoyl-2-pyrrolidinyl)methyl]Ala-Pro-OCH,(31). A mixture of diester 26 (110 mg, 0.275 mmol), Et3N (0.076 mL, 0.550 mmol), benzoic anhydride (62 mg, 0.275 mmol), and CH2Clz(5 mL) was stirred for 16 h. The product was purified on silica gel (EtOAc-EtOH, 31): TLC Rf 0.45; NMR (CDC13)6 1.24,1.31 (3 H, 2 d, J =7 Hz), 1.8-2.2 (8 H, m), 3.4-3.6 (4 H, m), 3.72 (3 H, s), 3.77 (3 H, s), 4.02 (1 H, d, J = 6 Hz), 4.14 (1 H, q, J = 6 Hz), 7.4-7.7 (5 H, m); MS, m/e 445 (M'). N-[Carboxy(N-benzoyl-2-pyrrolidinyl)methyl]-Ala-Pro (32). To a solution of diester 31 (79.5 mg, 0.179 mmol) in HzOCH30H (6:4,1.8 mL) was added aqueous NaOH (1 N, 0.72 mL). The mixture was stirred for 16 h and then placed directly onto Dowex 50; TLC ( C W A , 70306:4) Rf 0.40; NMR (CD30D)6 1.50, 1.53 (3 H, 2 d, J = 7 Hz), 1.8-2.4 (8 H, m), 3.3-3.6 (4 H, m), 3.9-4.1 (1H, m), 4.3-4.5 (2 H, m), 4.5-4.7 (1 H, m), 7.4-7.6 (5 H, m); MS, m/e 561 [M+ - bis(trimethylsilyl)]. N-[Carbomethoxy[[ N - (tert -butoxycarbonyl)glycyl]-2pyrrolidinyl]methyl]-Ala-Pro-OCH3 (33). A mixture of diester 26 (71.9 mg, 0.211 mmol),L-t-Boc-glycineN-hydroxysuccinimide ester (69 mg, 0.25 mmol), Et3N (0.035 mL, 0.25 mmol), and CH2Clz (2 mL) was stirred for 2 h and then evaporated to dryness. The product was purified on silica gel (ether-CH30H, 1O:l) and recrystallized (hexanes-EtOAc): 'IZC (ether-CH30H,20:l) Rf 0.15; NMR (CDCl3) 6 1.21,1.25 (3 H, 2 d, J = 7 Hz), 1.46 (9 H, s), 1.7-2.2 (8 H, m), 2.5-2.7 (2 H, m), 3.4-3.5 (3 H, m), 3.73 (3 H, s), 3.74 (3 H, s), 3.8-3.9 (2 H, m), 4.2 (1H, m), 4.5 (1H, m), 5.5 (1H, m); IR (CHC13)3430,2980,1730,1710,1430cm-'; MS, m/e 425 (M+ - 0-t-Bu). N - [Carboxy(N-glycyl-2-pyrrolidiny1)methyll-Ala-Pro (34). A mixture of diester 33 (40 mg, 0.080 mmol) and aqueous NaOH (0.25 N, 1.3 mL) was stirred for 24 h, diluted with aqueous HCl(O.50 N, 0.50 mL), and evaporated to dryness. The residue was taken up in concentrated HCl(5 mL) and stirred overnight. The mixture was diluted with HzO (15 mL) and then evaporated to dryness. The product was purified on Dowex 50 TLC (CMWA, 85:30:5:1) Rf 0.3; NMR (DzO) 6 1.31, 1.44 (3 H, 2 d, J = 7 Hz), 1.6-2.2 (8 H, m), 3.2-3.5 (5 H, m); 3.7-3.9 (1 H, m), 3.80 (2 H, s), 4.1-4.2 (1 H, m), 4.2-4.4 (1 H, m). N-[Carbomethoxy[N-[ (tert-butoxycarbonyl)phenylalanyl]-2-pyrrolidinyl]methyl]-Ala-Pro-OCH3 (36). A mixture of diester 26 (130 mg, 0.381 mmol), L-t-Boc-phenylalanineN hydroxysuccinimide ester (145 mg, 0.400 mmol), E t N (0.055 mL, 0.400 mmol), and CHzClz(3 mL) was stirred for 3 h and then evaporated to dryness. The product was purified on silica gel (CH2C12-CH,OH, 101): TLC RfO.5;NMR (CDC13) 6 1.08, 1.20 (3 H, 2 d, J = 7 Hz), 1.26, 1.38 (9 H, 2 s), 1.&2.2 (8H, m), 2.6-2.9 (2 H, m), 2.9-3.1 (2 H, m), 3.2-3.5 (5 H, m), 3.63, 3.69, 3.65, 3.67 (6 H, 4 s), 4.2-4.4 (3 H, m), 4.5-4.7 (1 H, m), 5.19, 5.34 (1H, 2 br d, J = 8 Hz); IR (CHC13)2960, 1730, 1710, 1640,1490, 1430 cm-l. N -[Carbomethoxy[N-(benzoylphenylalanyl)-2pyrrolidinyl]methyl]-Ala-Pro-OCH3 (37). A solution of diester 35 (64 mg, 0.109 mmol) in TFA (3 mL) was allowed to stand for 3 h and then evaporated to dryness. A mixture of the residue

Angiotensin-Converting Enzyme Inhibitors

Journal of Medicinal Chemistry, 1985, Vol. 28,No. 4 441

was stirred for 4 h and then neutralized with aqueous HCl(O.50 with benzoyl chloride (17mg, 0.12mmol), Et3N (0.075mL, 0.54 N, 0.21 mL). The product was purified on Dowex 50 TLC mmol), and CH2C12 (1 mL) was stirred overnight and then (EBAW, 1:l:l:l) R,0.20;NMR (DzO)6 1.53,1.60(3H, 2 d, J = evaporated to dryness. The residue was slurried in EtOAc and 7 Hz), 1.4-2.7(la H, m), 3.02 (2H, t, J = 8 Hz), 3.3-4.0(5 H, filtered. The product was purified on silica gel, giving a white m), 3.88(1 H, d, J = 2 Hz); 4.00 (1 H, q, J = 7 Hz), 4.2-4.5(2 solid: TLC (ether-CH,OH, 1O:l)Rf 0.3;NMR (CHCl3) 6 1.16, 1.28(3H,2d,J=7Hz),1.5-1.7(2H,m),1.8-2.2(6H,m),2.9-3.1H, m), 4.5-4.7(1 H, m); MS (FAB), m / e 553 (M' + 1). Compound 18s. To a solution of diester 26 (34.3mg, 0.100 (1 H, m), 3.2-3.6(6 H, m), 3.6-3.8(1 H, m), 3.68 (major), 3.76 mmol) in CHzClz(1mL) were added Et,N (20.2mg, 0.200mmol) (major), 3.62,3.70(6H, 4s), 4.3-4.4 (1 H, m), 4.4-4.5(1 H, m), and a solution of phosgene (1.1 M) in toluene (0.100mmol, 0.090 5.1-5.2(1 H, m), 6.92(major), 7.18 (1H, 2br d, J = 8 Hz), 7.2-7.8 mL). The mixture was stirred for 30 min and then evaporated. (10H, m); MS, m / e 592 (M'). A slurry of the residue in EtOAc was filtered and evaporated. The N-[Carboxy[N-(benzoylphenylalanyl)-2-pyrrolidinyl]product was purified on silica gel (EtQAc) and recrystallized methyl]-Ala-Pro (38). A mixture of diester 35 (57.5mg, 0.0971 (hexane-EtOAc),giving a white solid (28.5mg, 78%): mp 110-112 mmol), aqueous NaOH (0.25N, 1.55 mL), and CH30H (0.5 mL) "C; TLC (EtOAc) Rf 0.25;NMR (CDC13) 1.26 (3H, d, J = 7 Hz), was stirred overnight and then neutralized by addition of aqueous 1.3-2.3(7H, m), 3.12(1 H, ddd, J = 4,6,11 Hz); 3.56 (1H, dt, HCl(O.50 N, 0.75mL). The residue after evaporation was purified J = 11,6 Hz), 3.6-3.9 (2H, m), 3.71 (3 H, s), 3.76 (3H, s), 3.98 on Dowex 50 (HzO-CH30H-pyr, 1O:lOl): TLC (EBAW, 3:l:l:l) (1 H, td, J = 9,6 Hz), 4.30 (1 H, dd, J = 6,9 Hz), 4.48(1 H, d, Rf 0.45;NMR (DzO)6 1.07,1.14(3H, 2 d, J = 7), 1.4-1.9(8 H, J = 10 Hz); 4.94(1 H, 9, J = 9 Hz); IR (CHC13) 2960,1750,1690, m), 2.4-2.9(2H, m), 3.1-3.3 (2H, m), 3.4-3.6(2H, m), 3.8-4.1 1650,1415cm-'; MS, m / e 367 (M'). Anal. (C17H26N306)C, H, (3H, m), 4.2-4.4(1 H, m), 4.5-4.7(1H, m), 6.8-7.2(10H, m); N. MS, m / e 565 (M' + 1). Compound 18R. Amido ester 17R (0.442g, 1.29mmol) was N - [Carboxy(N-phenylalanyl-2-pyrrolidiny1)methyllcombined with Amberlyst 15resin (6g) and CH30H (10mL) and Ala-Pro(36). A mixture of diester 35 (65.8mg, 0.112mmol), the mixture was warmed at 60 "C for 5 days. Elution of the resin aqueous NaOH (0.25N, 1.8mL), and THF (1.8mL) was stirred with CH,OH-EhN (21)gave the crude diester, which was purified for 24 h and then diluted with aqueous HCl(O.50 N, 0.90mL). on silica gel (CMWA; 100:203:0.5). A solution of the resulting The residue after evaporation was dissolved in TFA and allowed acetate salt was dissolved in CHzClz(10ml) and neutralized with to stand for 3 h. The residue after evaporation was purified on anhydrous NH3. A portion of the resulting oil (87.2mg) was Dowex 50 TLC (EPAW,551:3)Rf 0.50;NMR (DzO)6 1.20,1.30 treated as described above for diester 26,affording 18R (16.1mg, (3H, 2 d, J = 7 Hz); 1.4-2.0(8 H, m), 2.5-2.7 (1H, m), 2.9-3.3 0.044 mmol, 17%). Recrystallization (hexane-EtOAc) gave a white (5H, m), 3.4-3.7(2H, m), 3.8-4.0 (1H, m), 4.0-4.2(2H, ); MS solid mp 97-99 "C; TLC (EtOAc) Rf 0.35;NMR (CDCl,) 6 1.36 (FAB), m / e 461 (M' 1). (1H, d, J = 7),1.5-2.3(7H, m), 3.03(1H, ddd, J = 4,7,11Hz), N*-Pyroglutamyl-Ne-carbobenzoxy-Lys-0t -Bu(39). A 3.4-3.8(4H, m), 3.71 (3 H, s), 3.79 (3H, s), 4.52(1 H, dd, J = solution of Nf-Cbz-Lys-O-t-Bu.HC1(l.OO g, 2.68mmol) in DMF 4,9 HZ), 4.81 (1 H, q, J = 7 HZ), 4.84 (1 H, d, J = 2 HZ);IR (6mL) was cooled (-20"C), and i-Pr2NEt(0.47mL, 2.70mmol), (CHCI,) 2970,1745,1695,1650,1420 cm-'; MS, m / e 367 (M'). pyroglutamic acid (0.346g, 2.68mmol), and DPPA (0.87mL, 4.0 Anal. (C17H26N306) C, H, N. mmol) were added in order. Then NaHC03 (1.3g, 15 mmol) was N-[Carboethoxy(N-benzoyl-2-pyrrolidinyl)methyl]-Alaadded. The mixture was stirred at -20 "C for 10 min, at 0 "C Pro-OEt(42). A mixture of amido ester 175 (97.8mg, 0.230 for 1h, and then at room temperature for 18h. The mixture was mmol), Amberlyst XN-1010acidic resido (1.5g), and anhydrous diluted with EtOAc (50 mL) and filtered. The filtrate was washed EtOH (4mL) was warmed at 70 "C for 9 days. Elution with with HzO, saturated NaHCO,, aqueous HCl(O.5 N), HzO, and EtOH-Et3N (2:l)gave a red-colored oil, which was chromatobrine, and dried (MgSOJ. The product was purified on silica gel graphed on silica gel (CMWA, 85305:l)and then treated briefly (EtOAc-EtOH, 20:1),giving a white solid mp 84-86"C (1.10 with anhydrous NH3 in CH2Cl2,affording N-[carboethoxy(2g, 2.45 mmol; 91%); TLC (EtOAc-EtOH, 20:l)Rf 0.35;NMR pyrrolidiny1)methyll-Ala-Pro-OEt(43)as a colorless oil (35.3mg, (CDCl,) 6 1.3-1.9(4H, m), 1.46(9H, s), 2.1-2.5 (4H, m), 2.8 (1 H,brs),2.93(1H,d,J=14Hz),3.1-3.3(2H,m),4.1-4.2(1H,0.0957 mmol, 42%): TLC (CMWA, 85:30:5:1)Rf 0.55;NMR (CDCl,) 6 1.2-1.4(9 H, m), 1.5-2.3(8 H, m), 3.2-3.4(1 H, m), m), 4.4-4.6 (1 H, s), 5.12(2H, s), 5.2-5.4 (1 H, br), 7.24(1 H, br 3.4-3.8 (5H, m), 4.1-4.3(5 H, m), 4.6-4.7(1 H, m); IR (CHC1,) s), 7.38(5 H, 8 ) ; MS, m / e 447 (M'). Anal. (C23H33H306), C, H, 2975,1720,1630cm:' This diester was combined with benzoic N. anhydride (22mg), Et3N (0.013mL, 0.099mmol), and CHzClz N - [Carbomethoxy(N"-pyroglutamyl-Nf-carbobenz(2mL). The mixture was stirred overnight and then diluted with oxylysyl-2-pyrrolidinyl)methyl]-Ala-Pro-OCH, (40). A soEtOAc (50mL) and filtered. Solvent was evaporated and the lution of ester 39 (0.155g, 0.335mmol) in TFA (5mL) was stirred product purified on silica gel (25mg, 0.053mmol, 55%): TLC for 6 h. The residue was purified on silica gel (CMWA, 85305:1), (CH2C12-CH30H,201)Rf0.30;NMR (CDC13)6 1.2-1.4(9H, m), giving N*-pyroglutamyl-N'-Cbz-Lys (52mg, 0.13mmol; 40%) as 1.5-2.3(8 H, m), 3.3-3.7(5 H, m), 4.0-4.2(5 H, m), 4.42 (1 H, a colorless oil: TLC (CH2Clz-CH30H,101)R 0.50; NMR (DzO) d of d, J = 4,sHz), 4.5-4.6(1 H, m), 7.3-7.6(5H, m); IR (CHClJ 6 1.3-1.8(4H, m), 2.2-2.6(4H, m), 3.1-3.2(2 H, br s), 3.3-3.4 2975,2880,1720,1630,1420 cm-'; MS, calcd for C2SN36N306 (2H, br s), 4.2-4.3(1 H, m), 5.10 (2 H, s), 7.36 (5 H, s). This 473.2524,found 473.2494. material (49.2,mg, 0.126mmol) was combined with N-methylN-[Carboethoxy(2-pyrrolidiny1)methyll-Ala-Pro.HCl(44). morpholine (0.0139mL, 0.126mmol) and THF (1 mL) under A solution of diester 42 (43.8mg, 0.0926mmol) in concentrated nitrogen. The solution was cooled (-15 "C) as isobutyl chloroHCl(3 mL) was stirred overnight, then diluted with HzO (50mL), formate (0.0163mL, 0.126 mmol) was added. After 2 min, a and evaporated to a white solid. Purification on silica gel (CMWA, solution of diester 26 (42.9mg, 0.126 mmol) in THF (1mL) was added. The mixture was stirred at -15 "C for 1h and then diluted 85:30:5:1)gave a white foam, which was taken up in HzO and filtered through Celite. Concentrated HCl(1 mL) was added to with EtOAc (50 mL) and extracted with saturated NaHCO,, HzO, the filtrate, which was then evaporated to a white solid (42.1mg, and brine. The solution was dried (MgS04) and concentrated 0.0874mmol, 94%): TLC (CMWA, 85:305:1)Rf0.75;NMR (DzO) to a colorless oil, which was purified on silica gel: TLC (EtOAeEtQH, 31)Rf 0.20;NMR (CDCl,) 6 1.23 (3H, d, J = 7 Hz), 61.34(3H,t,J=7H~),1.57(3H,dofd,J=4,10H~),1.7-2.4 1.4-2.5(16H, m), 3.1-3.3(2H, m), 3.4-3.8(9H, m), 3.68(3H, (8 H, m), 3.4-3.7(4H, m), 4.03(1 H, q, J = 7 Hz); 4.2-4.4(4H, s), 3.69 (3 H, s), 4.2-4.3(1H, m), 4.4-4.5 (1H, m), 4.3-4.4(1 H, m), 4.6-4.8(1 H, m), 7.5-7.7(5 H, m). m), 4.6-4.7(1 H, br), 5.11 (2H, s), 5.6-5.7(1 H, br), 7.37 (5 H, Acknowledgment. We thank Dr. J. Stevenson for s), 7.61(1H, br d, J = 7 Hz); IR (CHCl,) 1730,1720,1690,1630, FT-IR measurements a n d J. Smith for mass spectral 1420 cm-'; MS, mle 714 (M+). analyses. N-[ 1-Carboxy1-(N"-pyroglutamyllysyl-2-pyrrolidiny1)methyl]-Ala-Pro (41). A solution of diester 40 (25.0mg, 0.0352 Registry No. lR,94730-82-2; lS,94730-83-3; 2,84712-38-9; mmol) in CH30H (2 mL) was hydrogenated with 10% Pd(C) 3,72460-59-4; 4,69677-91-4; 5, 35084-74-3; 6 , 82001-60-3; 7, catalyst (10mg) for 3 h at 1 atm. Removal of catalyst by filtration 74075-33-5; 8, 72155-45-4; 9R,94670-41-4; 9S,94730-84-4; 10R, and evaporation gave a colorless residue (16.2mg), which was 94670-42-5; ios,94730-85-5;1IR,94798-95-5; lis,94670-43-6; combined with aqueous NaOH (0.25N, 0.56mL). The mixture 12R,94670-44-7; 125,94730-86-6; 13,69610-41-9; 14,94670-45-8;

+

J.Med. Chem. 1985,28,442-446

442

15,94670-46-9;16,6542-76-3;17R, 94670-47-0; 175,94730-87-7; 18R, 94670-48-1; 185,94730-88-8;19R, 84799-92-8; 195, 8475916-2; 20R, 94730-89-9; 20S, 94730-90-2; 21R, 94706-12-4; 215, 94798-96-6; 22,60398-41-6;23,60398-42-7;24,94706-13-5;25R, 94670-49-2; 255,94730-91-3; 26,94670-50-5;27,94670-51-6;28, 94670-52-7; 29, 94670-53-8; 30, 94670-54-9; 31, 94670-55-0; 32, 94670-56-1; 33, 94670-57-2; 34, 94670-58-3; 35, 94670-59-4; 36, 94670-60-7; 37, 94670-61-8; 38, 94706-14-6; 39, 94670-62-9; 40, 94670-63-0; 41, 94670-64-1; 42, 94670-65-2; 43, 94670-66-3; 44, 94670-67-4; aminoacetaldehyde diethyl acetal, 645-36-3; benzoyl chloride, 98-88-4; (N-benzoy1amino)acetaldehydediethyl acetal, 56459-72-4; di-tert-butyl dicarbonate, 24424-99-5; benzoic anhydride, 93-97-0;N-Boc-phenylalanine,13734-34-4;diazomethane,

334-88-3; N-((3-benzamido-l-carboxamido-4-pheny1) butyl)-AlaPro-OCH3, 94670-68-5; N-((3-benzamido-l-carbomethoxy-4phenyl)butyl)-Ala-Pro-OCH3, 94670-69-6; 3-[(tert-butoxycarbonyl)aminol-4-phenyl-l-butanol, 94670-70-9; 3-benzamido4-phenyl-1-butanol, 94706-15-7; Boc-glycine N-hydroxysuccinimide, 3392-07-2;(L)-Boc-phenylalanineN-hydroxysuccinimide, 3674-06-4; pyroglutamic acid, 98-79-3; phosgene, 75-44-5; angiotensin converting enzyme, 9015-82-1;(R)-N-((3-benzamido-lcarbomethoxy-4-pheny1)butyl)-Ala-Pro-OCH3, 94730-92-4; (8)N- ((3-benzamido-l-carbomethoxy-4-phenyl)butyl)-Ala-Pro-OCH3, 94730-93-5;Ala-Pro, 13485-59-1;N-t-Boc-Pro-OCH,, 59936-29-7; N'-Cbz-Lys-O-t-Bu.HCl, 5978-22-3;N*-pyroglutamyl-N'-Cbz-Lys, 94670-71-0.

Synthesis and Platelet Aggregation Inhibitory Activity of 4,5-Bis(substituted)-l,2,3-thiadiazoles Edward W. Thomas,* Edward E. Nishizawa, David C. Zimmermann, and Davey J. Williams Atherosclerosis and Thrombosis, The Upjohn Company, Kalamazoo, Michigan 49001. Received March 29, 1984 Routine screening of compounds for inhibition of collagen-inducedplatelet aggregation in vitro revealed 4,5-bis(4-methoxyphenyl)-l,2,3-thiadiazole (2) was active and it represents the first example of a 1,2,3-thiadiazolewith possible antithrombotic activity. In order to devleop a structure-activity relationship for this heterocycle, a number of new 4(5)-mono-and -disubstituted 1,2,34hiadiazoles were synthesized. These were tested in our screen and a number of additional active compounds were found. The most active compounds (2, 5a, 5b, and 6c) were those in which the heterocycle was substituted with benzene rings possessing para electron-donating groups.

A direct correlation has been drawn between platelet function and t h e development of cardiovascular disease states such as atherosclerosis' and its complications of myocardial infarction, transient ischemic attacks, and stroke." Cyclooxygenase inhibitors, which inhibit platelet aggregation induced by collagen and arachidonic acids, have been explored t o alter these disease state^.^^^ Yet, none of the platelet drugs has been overwhelmingly successful.' Since platelets may form a thrombus when exposed t o collagen as a result of a n arterial injury, we feel compounds that inhibit collagen-induced platelet aggregation would be of therapeutic interest. Recently one of us and others have reported a very interesting platelet-inhibitory compound Is t h a t has been shown to be active in vivo in humans? During the course of study with this compound, another antithrombotic compound was synthesized, thiadiazole 2. No one had previously shown t h a t this heterocyclic system possessed platelet inhibitory activity. N

I

N

2

I n order t o understand the structure-activity relationship of this heterocycle, we planned t o make a series of Woolf. N. Br. Med. Bull. 1978, 34, 137. Mitchell, J. R. A. Br. Med. Bull. 1978, 34, 103. Bouchier-Hayes, D. Zr. Med. J. 1983, 76, 101. Koch-Weser, J. N . Eng. J. Med. 1978,298, 1403. Genton, E.; Gent, M.; Hirsh, J.; Harker, L. A. N . Eng. J.Med.

1976,293,1174. Koch-Weser, J. N . Eng. J. Med. 1978, 298, 1403. Verstraete, M. Louuain Med. 1981, 100,453. Rynbrandt, R. H.; Nishizawa, E. E.; Balogoyen, D. P.; Mendoza, A. R.; Annis, K. A. J. Med. Chem. 1981,24, 1507. Linet, 0. I.; Eckert, S. M.; Gruber, C. A.; Huang, D. C. Circulation 1982, 66, 11-323.

Scheme I

4

3 X = C(0)OEt

or

5

S02C,H4Me

analogues and test them in vitro by the method of Born and Cross.l0 By synthesizing a number of 4- and 5-substituted 1,2,3-thiadiazoles, we discovered additional active drugs and the results are reported herein. We became interested in making analogues of the lead 1,2,3-thiadiazole due t o its high biological activity, the stability of this heterocycle, the ease of its synthesis, and the novelty of these compounds. 1,2,3-Thiadiazoles are thermally stable below 200 "C, they are stable in strong acid (HCl), and 4$-disubstituted thiadiazoles are stable t o reducing conditions.ll Although there are several methods available for the synthesis of this heterocyclic system, there are not many examples in the literature of structurally complex 1,2,3-thiadiazoles. We chose the method of Hurd and Mori12to synthesize 1,2,3-thiadiazoles in which a-methylene ketones or aldehydes are starting substrates (Scheme I). Many of the ketones and aldehydes used in this report were commercially available and some of those not commercially available were synthesized by standard Friedel-Crafts reaction conditions13 (Table I). Appropriate acid chlorides reacted with electron-rich phenyl groups, in t h e presence of aluminum chloride, t o afford the corresponding ketones. Stannic chloride was (10) Born, G. V. R.; Cross, M. J. J. Physiol. 1963, 168, 178. (11) Thomas, E. W. "Comprehensive Heterocyclic Chemistry"; Potts, K. T., Ed.; Pergamon Press Ltd.: Oxford, 1984; Vol. 6, Chapter 4.24. (12) Hurd, C. D.; Mori, R. I. J. Am. Chem. SOC. 1956, 77, 5359.

(13) Olah, G. A. "Friedel-Crafts and Related Reactions"; Interscience Publishers: New York, 1963; Vol. 1.

0022-2623/85/1828-0442$01.50/00 - 1985 American Chemical Society